These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 24990240)

  • 1. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists.
    Sitkovsky MV; Hatfield S; Abbott R; Belikoff B; Lukashev D; Ohta A
    Cancer Immunol Res; 2014 Jul; 2(7):598-605. PubMed ID: 24990240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.
    Steingold JM; Hatfield SM
    Front Immunol; 2020; 11():570041. PubMed ID: 33117358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
    Hatfield SM; Sitkovsky M
    Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.
    Halpin-Veszeleiova K; Hatfield SM
    Curr Opin Pharmacol; 2020 Aug; 53():84-90. PubMed ID: 32841869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Justifications of Systemic Therapeutic Oxygenation of Tumors to Weaken the Hypoxia Inducible Factor 1α-Mediated Immunosuppression.
    Hatfield S; Veszeleiova K; Steingold J; Sethuraman J; Sitkovsky M
    Adv Exp Med Biol; 2019; 1136():113-121. PubMed ID: 31201720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia.
    Sitkovsky MV; Kjaergaard J; Lukashev D; Ohta A
    Clin Cancer Res; 2008 Oct; 14(19):5947-52. PubMed ID: 18829471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sufficient numbers of anti-tumor T cells is a condition of maximal efficacy of anti-hypoxia-A2-adenosinergic drugs during cancer immunotherapy.
    Sitkovsky MV
    Curr Opin Pharmacol; 2020 Aug; 53():98-100. PubMed ID: 32861959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-κB enhances hypoxia-driven T-cell immunosuppression via upregulation of adenosine A(2A) receptors.
    Bruzzese L; Fromonot J; By Y; Durand-Gorde JM; Condo J; Kipson N; Guieu R; Fenouillet E; Ruf J
    Cell Signal; 2014 May; 26(5):1060-7. PubMed ID: 24486403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer.
    Sitkovsky M; Ohta A
    J Mol Med (Berl); 2013 Feb; 91(2):147-55. PubMed ID: 23334369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A
    Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
    J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A2A adenosine receptor protects tumors from antitumor T cells.
    Ohta A; Gorelik E; Prasad SJ; Ronchese F; Lukashev D; Wong MK; Huang X; Caldwell S; Liu K; Smith P; Chen JF; Jackson EK; Apasov S; Abrams S; Sitkovsky M
    Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13132-7. PubMed ID: 16916931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection.
    Hatfield SM; Kjaergaard J; Lukashev D; Belikoff B; Schreiber TH; Sethumadhavan S; Abbott R; Philbrook P; Thayer M; Shujia D; Rodig S; Kutok JL; Ren J; Ohta A; Podack ER; Karger B; Jackson EK; Sitkovsky M
    J Mol Med (Berl); 2014 Dec; 92(12):1283-92. PubMed ID: 25120128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
    Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
    Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.
    Sitkovsky MV
    Trends Immunol; 2009 Mar; 30(3):102-8. PubMed ID: 19201652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy.
    Kurago Z; Guo G; Shi H; Bollag RJ; Groves MW; Byrd JK; Cui Y
    Front Immunol; 2023; 14():1212209. PubMed ID: 37435071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD39/CD73/A2AR pathway and cancer immunotherapy.
    Xia C; Yin S; To KKW; Fu L
    Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adenosinergic immunomodulatory drugs.
    Ohta A; Sitkovsky M
    Curr Opin Pharmacol; 2009 Aug; 9(4):501-6. PubMed ID: 19539527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antihypoxia-adenosinergic pathogenesis as a result of collateral damage by overactive immune cells.
    Hatfield S; Belikoff B; Lukashev D; Sitkovsky M; Ohta A
    J Leukoc Biol; 2009 Sep; 86(3):545-8. PubMed ID: 19564571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting adenosine for cancer immunotherapy.
    Leone RD; Emens LA
    J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.